Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

NCT06549530 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Monkeypox (Mpox)

Interventions

DRUG: MVA-BN

Sponsor

Bavarian Nordic

Collaborators

[object Object]